Neogenomics Logo
Menu

Tests tables layout

hero anchor
Solid Tissue test
Liquid Test
Solid Tissue test
NEO | PanTracer Tissue

Comprehensive tissue profiling

Broad tissue-based CGP covering 517 genes with DNA + RNA sequencing for optimized fusion detection. Aligns with clinical guidelines and requires minimal tissue, enabling personalized therapy selection and trial matching.

Turnaround Time:
8-10 Days

New York Approved: Yes

517-gene pan-solid
tumor NGS panel

Detects: SNVs, InDels, CNVs, RNA fusions, splice variants 
Includes MSI* and TMB

No HRD analysis
--
--
NEO | PanTracer Tissue + HRD

Comprehensive tissue profiling + HRD

Comprehensive tissue-based CGP with integrated HRD scoring (BRCA1/2 + GIS: LOH, TAI, LST) to guide personalized therapy—supporting precision care across the ovarian cancer continuum.

Turnaround Time:
8-10 Days

New York Approved: No

517-gene pan-solid 
tumor NGS panel

Detects: SNVs, InDels, CNVs, RNA fusions, splice variants Includes MSI* and TMB

HRD assessment included

Homologous recombination deficiency  (HRD) status for ovarian tumors

--
--
NEO PanTracer Pro

Enhances ordering, auto-adds IHCs, ensures billing transparency

Enhanced ordering solution (launching January) that automatically adds IHC panels based on indication and includes a required legal PDF link for billing transparency.

Turnaround Time:
8-10 Days

New York Approved: Yes

517-gene pan-solid 
tumor NGS panel

Detects: SNVs, InDels, CNVs, RNA fusions, splice variants Includes MSI* and TMB

HRD assessment included

Homologous recombination deficiency (HRD) status for ovarian tumors

Adds IHC panels 

(based on indication)

--
Liquid Test
NEO | PanTracer LBx

When tissue is unavailable or monitoring needed

Liquid biopsy CGP analyzing 514 genes from a simple blood draw. Provides high-sensitivity ctDNA insights for real-time decisions when tissue is limited, inadequate, or not feasible.

Turnaround Time:
7 Days

New York Approved: No

514-gene liquid biopsy 
NGS panel

Detects: SNVs, InDels, CNVs, Fusions (DNA-based only; no RNA sequencing)

No HRD analysis
--
--
Tab 1
Tab 2
Tab 1

Next-Generation Sequencing

Flexible, high-throughput sequencing across platforms:

  • Illumina: NovaSeq X, NovaSeq 6000, NextSeq 500/550, MiSeq
  • Thermo Fisher: Ion Torrent Genexus, PGM Dx and Ion S5 Prime

Comprehensive Genomic Profiling

  • Identify rare variants down to 3% allele frequencies - lower option for exploratory studies
  • NGS assays for solid tumors and hematologic malignancies supporting clinical trials and translational research
  • Data analysis pipelines for DNA and RNA variant detection, tumor fraction estimation, clonality and resistance tracking, longitudinal monitoring, visualization, or custom analyses

Neo RaDaR® ST for Pharma Partners

Unlock the power of tumor-informed MRD detection with the RaDaR ST assay, delivering real-time molecular insights and high-sensitivity ctDNA analysis to identify residual disease with confidence.

  • Track tumor dynamics in real time
  • Design smarter, more adaptive clinical trials
  • Accelerate real-world impact across oncology pipelines

Learn more about the RaDaR ST assay and how it's redefining MRD-driven decision-making

TSO 500 Portfolio

TSO 500 HT Tissue and TSO 500 ctDNA v2 for broad genomic profiling to support biomarker discovery, target analysis, resistance detection, and longitudinal monitoring.

Learn more about TSO 500 solution for genomic profiling

 

We also offers RareCyte® liquid biopsy service.

Additional NGS Services

Suite of NGS assays for exploratory and research purposes with full bioinformatics support for comprehensive analysis. Includes customizable workflow options such as increased coverage to enhance sensitivity.

  • Whole Genome Sequencing (WGS)
  • Whole Exome Sequencing (WES)
  • Whole Transcriptome Sequencing (WTS)
  • RNA Exome Sequencing

Tab 2

Simple blood sample. Deep insights. One comprehensive panel

A comprehensive, noninvasive liquid biopsy (ctDNA) lab developed test for solid tumors - enabling biomarker discovery, resistance detection, and longitudinal monitoring - empowering data-driven decisions even when tumor tissue is limited or unavailable.

  • 514 cancer-relevant genes
    • SNVs and InDels – 514 genes
    • CNVs – 58 genes
    • Fusions – 23 genes
    • IO gene signatures (bMSI; bTMB score)
  • High performance ctDNA assay
Variant ClassAnalytical SensitivitySpecificityAccuracyLOD*
SNVs/InDels92.01%99.80%99.65%0.23%
CNVs95%99.86%99.82%1.20 fold
Fusions100%100%100%0.5%

*LOD90 at 30ng input